ESMO 2018 | IMpower150: atezolizumab, chemotherapy and bevacizumab for NSCLC

Martin Reck

Martin Reck, MD, PhD, of the Lung Clinic Grosshansdorf, Grosshansdorf, Germany, provides an update on the IMpower150 trial (NCT02366143) of atezolizumab, bevacizumab and chemotherapy for untreated, advanced non-small cell lung cancer. Prof. Reck highlights the exceedingly promising results and gives his insight into the responses of different subgroups of the trials. This interview took place at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.

Share this video